S-nitrosoglutathione (GSNO) is cytotoxic to intracellular amastigotes and promotes healing of topically treated leishmania major or leishmania braziliensis skin lesions

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 11, 2013, Pages 2561-2568

  Costa, Inez Silva Fernandes ^a   de Souza, Gabriela Freitas Pereira ^b   de Oliveira, Marcelo Ganzarolli ^b   Abrahamsohn, Ises de Almeida ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Localized cutaneous leishmaniasis lcl; Nitric oxide donor molecules; S nitrosothiols; Therapy

Indexed keywords

AMPHOTERICIN B; GAMMA INTERFERON; S NITROSOGLUTATHIONE;

AMASTIGOTE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; IMMUNOFLUORESCENCE; IN VITRO STUDY; LEISHMANIA; LEISHMANIA BRAZILIENSIS; LEISHMANIA MAJOR; LYMPH NODE; MACROPHAGE; MACROPHAGE CULTURE; MOUSE; NONHUMAN; PARASITE LOAD; SKIN DEFECT; SKIN LEISHMANIASIS; SKIN ULCER;

LOCALIZED CUTANEOUS LEISHMANIASIS-LCL; NITRIC OXIDE DONOR MOLECULES; S-NITROSOTHIOLS; THERAPY;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIPARASITIC AGENTS; DISEASE MODELS, ANIMAL; FEMALE; LEISHMANIA BRAZILIENSIS; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PARASITE LOAD; S-NITROSOGLUTATHIONE; SKIN; TREATMENT OUTCOME; ULCER;

EID: 84886301484     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt210     Document Type: Article

References (46)

1. GotoH, Lindoso JA. Cutaneousandmucocutaneousleishmaniasis. Infect Dis Clin North Am 2012; 26: 293-307.
2. Khatami A, Firooz A, Gorouhi F et al. Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J Am Acad Dermatol 2007; 57: 335 e1-29.
3. Reithinger R, Dujardin JC, Louzir H et al. Cutaneous leishmaniasis. Lancet Infect Dis 2007; 7: 581-96.
4. Schriefer A, Wilson ME, Carvalho EM. Recent developments leading toward a paradigm switch in the diagnostic and therapeutic approach to human leishmaniasis. Curr Opin Infect Dis 2008; 21: 483-8.
5. MurrayHW. Leishmaniasis in the United States: treatment in 2012. Am J Trop Med Hyg 2012; 86: 434-40.
6. Tuon FF, Amato VS, Graf ME et al. Treatment of New World cutaneous leishmaniasis-a systematic review with a meta-analysis. Int J Dermatol 2008; 47: 109-24.
7. Croft SL, Coombs GH. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003; 19: 502-8.
8. Machado PR, Penna G. Miltefosine and cutaneous leishmaniasis. Curr Opin Infect Dis 2012; 25: 141-4.
9. Sousa AQ, Frutuoso MS, Moraes EA et al. High-dose oral fluconazole therapy effective for cutaneous leishmaniasis due to Leishmania (Vianna) braziliensis. Clin Infect Dis 2011; 53: 693-5.
10. Garnier T, Croft SL. Topical treatment for cutaneous leishmaniasis. Curr Opin Investig Drugs 2002; 3: 538-44.
11. Seifert K. Structures, targets and recent approaches in anti-leishmanial drug discovery and development. Open Med Chem J 2011; 5: 31-9.
12. ModabberF, BuffetPA, TorreeleEet al. Consultativemeetingtodevelopa strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13-15 June, 2006. Kinetoplastid Biol Dis 2007; 6: 3.
13. de Oliveira CI, Brodskyn CI. The immunobiology of Leishmania braziliensis infection. Front Immunol 2012; 3: 145.
14. Mougneau E, Bihl F, Glaichenhaus N. Cell biology and immunology of Leishmania. Immunol Rev 2011; 240: 286-96.
15. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002; 2: 845-58.
16. Holzmuller P, Bras-Goncalves R, Lemesre JL. Phenotypical characteristics, biochemical pathways, molecular targets and putative role of nitric oxide-mediated programmed cell death in Leishmania. Parasitology 2006; 132 Suppl: S19-32.
17. Liew FY, Millott S, Parkinson C et al. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol 1990; 144: 4794-7.
18. Burgaud JL, Riffaud JP, Del Soldato P. Nitric-oxide releasing molecules: a new class of drugs with several major indications. Curr Pharm Des 2002; 8: 201-13.
19. Scatena R, Bottoni P, Martorana GE et al. Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential. Expert Opin Investig Drugs 2005; 14: 835-46.
20. Zeina B, Banfield C, al-Assad S. Topical glyceryl trinitrate: a possible treatment for cutaneous leishmaniasis. Clin Exp Dermatol 1997; 22: 244-5.
21. Davidson RN, Yardley V, Croft SL et al. A topical nitric oxide-generating therapy for cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 2000; 94: 319-22.
22. Lopez-Jaramillo P, Smith DJ. Controlled nitric oxide releasing patch versus meglumine antimoniate in the treatment of cutaneous leishmaniasis NCT00317629. Clinical Trialsgov, 2010. http://clinicaltrials. gov/ct2/show/NCT00317629?term=NCT00317629&rank=1 (3 June 2013, date last accessed).
23. Clancy RM, Levartovsky D, Leszczynska-Piziak J et al. Nitric oxide reacts with intracellular glutathione and activates the hexose monophosphate shunt in human neutrophils: evidence for S-nitrosoglutathione as a bioactive intermediary. Proc Natl Acad Sci USA 1994; 91: 3680-4.
24. Hogg N. Biological chemistry and clinical potential of S-nitrosothiols. Free Radic Biol Med 2000; 28: 1478-86.
25. Zhang Y, Hogg N. S-nitrosothiols: cellular formation and transport. Free Radic Biol Med 2005; 38: 831-8.
26. Van Assche T, Deschacht M, da Luz RA et al. Leishmania-macrophage interactions: insights into the redox biology. Free Radic Biol Med 2011; 51: 337-51.
27. Salvati L, Mattu M, Colasanti M et al. NO donors inhibit Leishmania infantum cysteine proteinase activity. Biochim Biophys Acta 2001; 1545: 357-66.
28. Holzmuller P, Sereno D, Cavaleyra M et al. Nitric oxide-mediated proteasome-dependent oligonucleosomal DNA fragmentation in Leishmania amazonensis amastigotes. Infect Immun 2002; 70: 3727-35.
29. Lopez-Jaramillo P, Ruano C, Rivera J et al. Treatment of cutaneous leishmaniasis with nitric-oxide donor. Lancet 1998; 351: 1176-7.
30. de Souza GF, Yokoyama-Yasunaka JK, Seabra AB et al. Leishmanicidal activity of primary S-nitrosothiols against Leishmania major and Leishmania amazonensis: implications for the treatment of cutaneous leishmaniasis. Nitric Oxide 2006; 15: 209-16.
31. Oliveira MA, Pires Ada S, de Bastos RP et al. Leishmania spp. parasite isolation through inoculation of patient biopsy macerates in interferon g knockout mice. Rev Inst Med Trop Sao Paulo 2010; 52: 83-8.
32. Hart TW. Some observations concerning the S-nitroso and S-phenylsulphonyl derivatives of L-cysteine and glutathione. Tetrahedron Lett 1985; 16: 2013-6.
33. Hongo F, Garban H, Huerta-Yepez S et al. Inhibition of the transcription factor Yin Yang 1 activity by S-nitrosation. Biochem Biophys Res Commun 2005; 336: 692-701.
34. Afonso LC, Scott P. Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect Immun 1993; 61: 2952-9.
35. Lemesre JL, Sereno D, Daulouede S et al. Leishmania spp. nitric oxide-mediated metabolic inhibition of promastigote and axenically grown amastigote forms. Exp Parasitol 1997; 86: 58-68.
36. Mauel J, Ransijn A. Leishmania spp. mechanisms of toxicity of nitrogen oxidation products. Exp Parasitol 1997; 87: 98-111.
37. Genestra M, Soares-Bezerra RJ, Gomes-Silva L et al. In vitro sodium nitroprusside-mediated toxicity towards Leishmania amazonensis promastigotes and axenic amastigotes. Cell Biochem Funct 2008; 26: 709-17.
38. Cariello AJ, Bispo PJM, de Souza GFP et al. Bactericidal effect of S-nitrosothiols against clinical isolates from keratitis. Clin Ophthalmol 2012; 6: 1-8.
39. Cariello AJ, de Souza GF, Foronda AS et al. In vitro amoebicidal activity of S-nitrosoglutathione and S-nitroso-N-acetylcysteine against trophozoites of Acanthamoeba castellanii. J Antimicrob Chemother 2010; 65: 588-91.
40. Ei-On J, Jacobs GP, Weinrauch L. Topical chemotherapy of cutaneous leishmaniasis. Parasitol Today 1988; 4: 76-81.
41. Lecoeur H, Buffet PA, Milon G et al. Early curative applications of the aminoglycoside WR279396 on an experimental Leishmania major-loaded cutaneous site do not impair the acquisition of immunity. Antimicrob Agents Chemother 2010; 54: 984-90.
42. AmadeuTP,SeabraAB,de OliveiraMGetal. Nitricoxidedonorimproveshealing if applied on inflammatory and proliferative phase. J Surg Res 2008; 149: 84-93.
43. Georgii JL, Amadeu TP, Seabra AB et al. Topical S-nitrosoglutathionereleasing hydrogel improves healing of rat ischaemic wounds. J Tissue Eng Regen Med 2011; 5: 612-9.
44. Oliveira F, Bafica A, Rosato AB et al. Lesion size correlates with Leishmania antigen-stimulated TNF-levels in human cutaneous leishmaniasis. Am J Trop Med Hyg 2011; 85: 70-3.
45. Sakthianandeswaren A, Curtis JM, Elso C et al. Fine mapping of Leishmania major susceptibility locus lmr2 and evidence of a role for Fli1 in disease and wound healing. Infect Immun 2010; 78: 2734-44.
46. Dalton DK, Pitts-Meek S, Keshav S et al. Multiple defects of immune cell function in mice with disrupted interferon-g genes. Science 1993; 259: 1739-42.